APO Research
Talk to an analyst

APO RESEARCH · REPORT

NGS for Cancer Early Screening

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global NGS for Cancer Early Screening Industry Growth and Trends Forecast to 2032

15 April 2026112 pages

Choose your research edition.

Industry ResearchNGS for Cancer Early Screening Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal NGS for Cancer Early Screening Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal NGS for Cancer Early Screening Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal NGS for Cancer Early Screening Market Outlook and Growth Opportunities 2026$4,250 USDMarket Analysis & ForecastGlobal NGS for Cancer Early Screening Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

According to APO Research, the global NGS for Cancer Early Screening market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for NGS for Cancer Early Screening is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for NGS for Cancer Early Screening is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for NGS for Cancer Early Screening is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the NGS for Cancer Early Screening market include Guardant Health, Exact Sciences, Freenome, Epiginomics AG, Bio-techne, ThriveEarlier Detection, GRAIL, Inc., CellMax life and Berry Genomics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global NGS for Cancer Early Screening market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The NGS for Cancer Early Screening market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global NGS for Cancer Early Screening market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to NGS for Cancer Early Screening.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global NGS for Cancer Early Screening market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

NGS for Cancer Early Screening Market by Company

Guardant Health

Exact Sciences

Freenome

Epiginomics AG

Bio-techne

ThriveEarlier Detection

GRAIL, Inc.

CellMax life

Berry Genomics

Singlera Genomics

Geneseeq

BGI Genomics

Burning Rock Biotech Limited

New Horizon Health Limited

Yeasen Bio

Hangzhou Aoru Biotech

Amoy Diagnostics Co., Ltd.

Genetron Health

AnchorDx

NGS for Cancer Early Screening Segment by Type

ctDNA Gene Mutation Detection

cfDNA Methylation Sequencing

NGS for Cancer Early Screening Segment by Application

Medical Institutions

Physical Examination Centers

NGS for Cancer Early Screening Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global NGS for Cancer Early Screening market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of NGS for Cancer Early Screening and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of NGS for Cancer Early Screening.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of NGS for Cancer Early Screening companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global NGS for Cancer Early Screening Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global NGS for Cancer Early Screening Market Size by Region (2021-2026) & (US$ Million) Table 3. Global NGS for Cancer Early Screening Market Share by Region (2021-2026) Table 4. Global NGS for Cancer Early Screening Market Size by Region (2027-2032) & (US$ Million) Table 5. Global NGS for Cancer Early Screening Market Share by Region (2027-2032) Table 6. Global NGS for Cancer Early Screening Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global NGS for Cancer Early Screening Market Size by Type (2021-2026) & (US$ Million) Table 8. Global NGS for Cancer Early Screening Market Size Share by Type (2021-2026) Table 9. Global NGS for Cancer Early Screening Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global NGS for Cancer Early Screening Market Size Share Forecasted by Type (2027-2032) Table 11. North America NGS for Cancer Early Screening Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America NGS for Cancer Early Screening Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe NGS for Cancer Early Screening Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe NGS for Cancer Early Screening Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific NGS for Cancer Early Screening Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific NGS for Cancer Early Screening Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America NGS for Cancer Early Screening Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America NGS for Cancer Early Screening Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa NGS for Cancer Early Screening Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa NGS for Cancer Early Screening Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global NGS for Cancer Early Screening Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global NGS for Cancer Early Screening Market Size by Application (2021-2026) & (US$ Million) Table 23. Global NGS for Cancer Early Screening Market Size Share by Application (2021-2026) Table 24. Global NGS for Cancer Early Screening Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global NGS for Cancer Early Screening Market Size Share Forecasted by Application (2027-2032) Table 26. North America NGS for Cancer Early Screening Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America NGS for Cancer Early Screening Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe NGS for Cancer Early Screening Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe NGS for Cancer Early Screening Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific NGS for Cancer Early Screening Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific NGS for Cancer Early Screening Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America NGS for Cancer Early Screening Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America NGS for Cancer Early Screening Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa NGS for Cancer Early Screening Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa NGS for Cancer Early Screening Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. NGS for Cancer Early Screening Industry Trends Table 37. NGS for Cancer Early Screening Industry Drivers Table 38. NGS for Cancer Early Screening Industry Opportunities and Challenges Table 39. NGS for Cancer Early Screening Industry Restraints Table 40. Global NGS for Cancer Early Screening Revenue by Company (US$ Million) & (2021-2026) Table 41. Global NGS for Cancer Early Screening Revenue Market Share by Company (2021-2026) Table 42. Global NGS for Cancer Early Screening Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global NGS for Cancer Early Screening Key Company Headquarters & Area Served Table 44. Global NGS for Cancer Early Screening Company, Product Type & Application Table 45. Global NGS for Cancer Early Screening Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global NGS for Cancer Early Screening by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Guardant Health Company Information Table 49. Guardant Health Business Overview Table 50. Guardant Health NGS for Cancer Early Screening Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Guardant Health NGS for Cancer Early Screening Product Portfolio Table 52. Guardant Health Recent Development Table 53. Exact Sciences Company Information Table 54. Exact Sciences Business Overview Table 55. Exact Sciences NGS for Cancer Early Screening Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Exact Sciences NGS for Cancer Early Screening Product Portfolio Table 57. Exact Sciences Recent Development Table 58. Freenome Company Information Table 59. Freenome Business Overview Table 60. Freenome NGS for Cancer Early Screening Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Freenome NGS for Cancer Early Screening Product Portfolio Table 62. Freenome Recent Development Table 63. Epiginomics AG Company Information Table 64. Epiginomics AG Business Overview Table 65. Epiginomics AG NGS for Cancer Early Screening Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Epiginomics AG NGS for Cancer Early Screening Product Portfolio Table 67. Epiginomics AG Recent Development Table 68. Bio-techne Company Information Table 69. Bio-techne Business Overview Table 70. Bio-techne NGS for Cancer Early Screening Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Bio-techne NGS for Cancer Early Screening Product Portfolio Table 72. Bio-techne Recent Development Table 73. ThriveEarlier Detection Company Information Table 74. ThriveEarlier Detection Business Overview Table 75. ThriveEarlier Detection NGS for Cancer Early Screening Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. ThriveEarlier Detection NGS for Cancer Early Screening Product Portfolio Table 77. ThriveEarlier Detection Recent Development Table 78. GRAIL, Inc. Company Information Table 79. GRAIL, Inc. Business Overview Table 80. GRAIL, Inc. NGS for Cancer Early Screening Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. GRAIL, Inc. NGS for Cancer Early Screening Product Portfolio Table 82. GRAIL, Inc. Recent Development Table 83. CellMax life Company Information Table 84. CellMax life Business Overview Table 85. CellMax life NGS for Cancer Early Screening Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. CellMax life NGS for Cancer Early Screening Product Portfolio Table 87. CellMax life Recent Development Table 88. Berry Genomics Company Information Table 89. Berry Genomics Business Overview Table 90. Berry Genomics NGS for Cancer Early Screening Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. Berry Genomics NGS for Cancer Early Screening Product Portfolio Table 92. Berry Genomics Recent Development Table 93. Singlera Genomics Company Information Table 94. Singlera Genomics Business Overview Table 95. Singlera Genomics NGS for Cancer Early Screening Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. Singlera Genomics NGS for Cancer Early Screening Product Portfolio Table 97. Singlera Genomics Recent Development Table 98. Geneseeq Company Information Table 99. Geneseeq Business Overview Table 100. Geneseeq NGS for Cancer Early Screening Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. Geneseeq NGS for Cancer Early Screening Product Portfolio Table 102. Geneseeq Recent Development Table 103. BGI Genomics Company Information Table 104. BGI Genomics Business Overview Table 105. BGI Genomics NGS for Cancer Early Screening Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. BGI Genomics NGS for Cancer Early Screening Product Portfolio Table 107. BGI Genomics Recent Development Table 108. Burning Rock Biotech Limited Company Information Table 109. Burning Rock Biotech Limited Business Overview Table 110. Burning Rock Biotech Limited NGS for Cancer Early Screening Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 111. Burning Rock Biotech Limited NGS for Cancer Early Screening Product Portfolio Table 112. Burning Rock Biotech Limited Recent Development Table 113. New Horizon Health Limited Company Information Table 114. New Horizon Health Limited Business Overview Table 115. New Horizon Health Limited NGS for Cancer Early Screening Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 116. New Horizon Health Limited NGS for Cancer Early Screening Product Portfolio Table 117. New Horizon Health Limited Recent Development Table 118. Yeasen Bio Company Information Table 119. Yeasen Bio Business Overview Table 120. Yeasen Bio NGS for Cancer Early Screening Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 121. Yeasen Bio NGS for Cancer Early Screening Product Portfolio Table 122. Yeasen Bio Recent Development Table 123. Hangzhou Aoru Biotech Company Information Table 124. Hangzhou Aoru Biotech Business Overview Table 125. Hangzhou Aoru Biotech NGS for Cancer Early Screening Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 126. Hangzhou Aoru Biotech NGS for Cancer Early Screening Product Portfolio Table 127. Hangzhou Aoru Biotech Recent Development Table 128. Amoy Diagnostics Co., Ltd. Company Information Table 129. Amoy Diagnostics Co., Ltd. Business Overview Table 130. Amoy Diagnostics Co., Ltd. NGS for Cancer Early Screening Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 131. Amoy Diagnostics Co., Ltd. NGS for Cancer Early Screening Product Portfolio Table 132. Amoy Diagnostics Co., Ltd. Recent Development Table 133. Genetron Health Company Information Table 134. Genetron Health Business Overview Table 135. Genetron Health NGS for Cancer Early Screening Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 136. Genetron Health NGS for Cancer Early Screening Product Portfolio Table 137. Genetron Health Recent Development Table 138. AnchorDx Company Information Table 139. AnchorDx Business Overview Table 140. AnchorDx NGS for Cancer Early Screening Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 141. AnchorDx NGS for Cancer Early Screening Product Portfolio Table 142. AnchorDx Recent Development Table 143. North America NGS for Cancer Early Screening Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 144. North America NGS for Cancer Early Screening Market Size by Country (2021-2026) & (US$ Million) Table 145. North America NGS for Cancer Early Screening Market Share by Country (2021-2026) Table 146. North America NGS for Cancer Early Screening Market Size Forecast by Country (2027-2032) & (US$ Million) Table 147. North America NGS for Cancer Early Screening Market Share Forecast by Country (2027-2032) Table 148. Europe NGS for Cancer Early Screening Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 149. Europe NGS for Cancer Early Screening Market Size by Country (2021-2026) & (US$ Million) Table 150. Europe NGS for Cancer Early Screening Market Share by Country (2021-2026) Table 151. Europe NGS for Cancer Early Screening Market Size Forecast by Country (2027-2032) & (US$ Million) Table 152. Europe NGS for Cancer Early Screening Market Share Forecast by Country (2027-2032) Table 153. Asia-Pacific NGS for Cancer Early Screening Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 154. Asia-Pacific NGS for Cancer Early Screening Market Size by Country (2021-2026) & (US$ Million) Table 155. Asia-Pacific NGS for Cancer Early Screening Market Share by Country (2021-2026) Table 156. Asia-Pacific NGS for Cancer Early Screening Market Size Forecast by Country (2027-2032) & (US$ Million) Table 157. Asia-Pacific NGS for Cancer Early Screening Market Share Forecast by Country (2027-2032) Table 158. Latin America NGS for Cancer Early Screening Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 159. Latin America NGS for Cancer Early Screening Market Size by Country (2021-2026) & (US$ Million) Table 160. Latin America NGS for Cancer Early Screening Market Share by Country (2021-2026) Table 161. Latin America NGS for Cancer Early Screening Market Size Forecast by Country (2027-2032) & (US$ Million) Table 162. Latin America NGS for Cancer Early Screening Market Share Forecast by Country (2027-2032) Table 163. Middle East & Africa NGS for Cancer Early Screening Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 164. Middle East & Africa NGS for Cancer Early Screening Market Size by Country (2021-2026) & (US$ Million) Table 165. Middle East & Africa NGS for Cancer Early Screening Market Share by Country (2021-2026) Table 166. Middle East & Africa NGS for Cancer Early Screening Market Size Forecast by Country (2027-2032) & (US$ Million) Table 167. Middle East & Africa NGS for Cancer Early Screening Market Share Forecast by Country (2027-2032) Table 168. Research Programs/Design for This Report Table 169. Authors List of This Report Table 170. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. NGS for Cancer Early Screening Product Image Figure 3. Global NGS for Cancer Early Screening Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global NGS for Cancer Early Screening Market Size (2021-2032) & (US$ Million) Figure 5. Global NGS for Cancer Early Screening Market Share by Region: 2025 VS 2032 Figure 6. Global NGS for Cancer Early Screening Market Share by Region (2021-2032) Figure 7. North America NGS for Cancer Early Screening Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe NGS for Cancer Early Screening Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific NGS for Cancer Early Screening Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America NGS for Cancer Early Screening Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa NGS for Cancer Early Screening Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. ctDNA Gene Mutation Detection Image Figure 13. Global ctDNA Gene Mutation Detection Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. cfDNA Methylation Sequencing Image Figure 15. Global cfDNA Methylation Sequencing Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Global NGS for Cancer Early Screening Market Size Overview by Type (2021-2032) & (US$ Million) Figure 17. Global NGS for Cancer Early Screening Market Share by Type 2025 VS 2032 Figure 18. North America NGS for Cancer Early Screening Market Size Share by Type (2021-2032) Figure 19. Europe NGS for Cancer Early Screening Market Size Share by Type (2021-2032) Figure 20. Asia-Pacific NGS for Cancer Early Screening Market Size Share by Type (2021-2032) Figure 21. Latin America NGS for Cancer Early Screening Market Size Share by Type (2021-2032) Figure 22. Middle East and Africa NGS for Cancer Early Screening Market Size Share by Type (2021-2032) Figure 23. Medical Institutions Image Figure 24. Global Medical Institutions Market Size YoY Growth (2021-2032) & (US$ Million) Figure 25. Physical Examination Centers Image Figure 26. Global Physical Examination Centers Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. Global NGS for Cancer Early Screening Market Size Overview by Application (2021-2032) & (US$ Million) Figure 28. Global NGS for Cancer Early Screening Market Share by Application 2025 VS 2032 Figure 29. North America NGS for Cancer Early Screening Market Size Share by Application (2021-2032) Figure 30. Europe NGS for Cancer Early Screening Market Size Share by Application (2021-2032) Figure 31. Asia-Pacific NGS for Cancer Early Screening Market Size Share by Application (2021-2032) Figure 32. Latin America NGS for Cancer Early Screening Market Size Share by Application (2021-2032) Figure 33. Middle East and Africa NGS for Cancer Early Screening Market Size Share by Application (2021-2032) Figure 34. Global Top 5 and 10 NGS for Cancer Early Screening Players Market Share by Revenue in 2025 Figure 35. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 36. North America NGS for Cancer Early Screening Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 37. North America NGS for Cancer Early Screening Market Share by Country: 2021 VS 2025 VS 2032 Figure 38. North America NGS for Cancer Early Screening Market Share by Country (2021-2032) Figure 39. Europe NGS for Cancer Early Screening Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 40. Europe NGS for Cancer Early Screening Market Share by Country: 2021 VS 2025 VS 2032 Figure 41. Europe NGS for Cancer Early Screening Market Share by Country (2021-2032) Figure 42. Asia-Pacific NGS for Cancer Early Screening Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 43. Asia-Pacific NGS for Cancer Early Screening Market Share by Country: 2021 VS 2025 VS 2032 Figure 44. Asia-Pacific NGS for Cancer Early Screening Market Share by Country (2021-2032) Figure 45. Latin America NGS for Cancer Early Screening Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. Latin America NGS for Cancer Early Screening Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Latin America NGS for Cancer Early Screening Market Share by Country (2021-2032) Figure 48. Middle East & Africa NGS for Cancer Early Screening Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 49. Middle East & Africa NGS for Cancer Early Screening Market Share by Country: 2021 VS 2025 VS 2032 Figure 50. Middle East & Africa NGS for Cancer Early Screening Market Share by Country (2021-2032) Figure 51. Years Considered Figure 52. Research Process Figure 53. Key Executives Interviewed

Scope & coverage.

Types
  • ctDNA Gene Mutation Detection
  • cfDNA Methylation Sequencing
Applications
  • Medical Institutions
  • Physical Examination Centers
Companies covered
  • Guardant Health
  • Exact Sciences
  • Freenome
  • Epiginomics AG
  • Bio-techne
  • ThriveEarlier Detection
  • GRAIL, Inc.
  • CellMax life
  • Berry Genomics
  • Singlera Genomics
  • Geneseeq
  • BGI Genomics
  • Burning Rock Biotech Limited
  • New Horizon Health Limited
  • Yeasen Bio
  • Hangzhou Aoru Biotech
  • Amoy Diagnostics Co., Ltd.
  • Genetron Health
  • AnchorDx

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global NGS for Cancer Early Screening Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global NGS for Cancer Early Screening Market Size by Region (2021-2032)
  5. 1.4.1 Global NGS for Cancer Early Screening Market Size by Region (2021-2026)
  6. 1.4.2 Global NGS for Cancer Early Screening Market Size by Region (2027-2032)
  7. 1.5 Key Regions NGS for Cancer Early Screening Market Size (2021-2032)
  8. 1.5.1 North America NGS for Cancer Early Screening Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe NGS for Cancer Early Screening Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific NGS for Cancer Early Screening Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America NGS for Cancer Early Screening Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa NGS for Cancer Early Screening Market Size Growth Rate (2021-2032)
2 NGS for Cancer Early Screening Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 ctDNA Gene Mutation Detection
  3. 2.1.2 cfDNA Methylation Sequencing
  4. 2.2 Global NGS for Cancer Early Screening Market Size by Type
  5. 2.2.1 Global NGS for Cancer Early Screening Market Size Overview by Type (2021-2032)
  6. 2.2.2 Global NGS for Cancer Early Screening Historic Market Size Review by Type (2021-2026)
  7. 2.2.3 Global NGS for Cancer Early Screening Market Size Forecasted by Type (2027-2032)
  8. 2.3 Global NGS for Cancer Early Screening Market Size by Regions
  9. 2.3.1 North America NGS for Cancer Early Screening Market Size Breakdown by Type (2021-2026)
  10. 2.3.2 Europe NGS for Cancer Early Screening Market Size Breakdown by Type (2021-2026)
  11. 2.3.3 Asia-Pacific NGS for Cancer Early Screening Market Size Breakdown by Type (2021-2026)
  12. 2.3.4 South America NGS for Cancer Early Screening Market Size Breakdown by Type (2021-2026)
  13. 2.3.5 Middle East and Africa NGS for Cancer Early Screening Market Size Breakdown by Type (2021-2026)
3 NGS for Cancer Early Screening Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Medical Institutions
  3. 3.1.2 Physical Examination Centers
  4. 3.2 Global NGS for Cancer Early Screening Market Size by Application
  5. 3.2.1 Global NGS for Cancer Early Screening Market Size Overview by Application (2021-2032)
  6. 3.2.2 Global NGS for Cancer Early Screening Historic Market Size Review by Application (2021-2026)
  7. 3.2.3 Global NGS for Cancer Early Screening Market Size Forecasted by Application (2027-2032)
  8. 3.3 Global NGS for Cancer Early Screening Market Size by Regions
  9. 3.3.1 North America NGS for Cancer Early Screening Market Size Breakdown by Application (2021-2026)
  10. 3.3.2 Europe NGS for Cancer Early Screening Market Size Breakdown by Application (2021-2026)
  11. 3.3.3 Asia-Pacific NGS for Cancer Early Screening Market Size Breakdown by Application (2021-2026)
  12. 3.3.4 South America NGS for Cancer Early Screening Market Size Breakdown by Application (2021-2026)
  13. 3.3.5 Middle East and Africa NGS for Cancer Early Screening Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 NGS for Cancer Early Screening Industry Trends
  2. 4.2 NGS for Cancer Early Screening Industry Drivers
  3. 4.3 NGS for Cancer Early Screening Industry Opportunities and Challenges
  4. 4.4 NGS for Cancer Early Screening Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by NGS for Cancer Early Screening Revenue (2021-2026)
  2. 5.2 Global NGS for Cancer Early Screening Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global NGS for Cancer Early Screening Key Company Headquarters & Area Served
  4. 5.4 Global NGS for Cancer Early Screening Company, Product Type & Application
  5. 5.5 Global NGS for Cancer Early Screening Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global NGS for Cancer Early Screening Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 NGS for Cancer Early Screening Players Market Share by Revenue in 2025
  9. 5.6.3 2025 NGS for Cancer Early Screening Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Guardant Health
  2. 6.1.1 Guardant Health Company Information
  3. 6.1.2 Guardant Health Business Overview
  4. 6.1.3 Guardant Health NGS for Cancer Early Screening Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Guardant Health NGS for Cancer Early Screening Product Portfolio
  6. 6.1.5 Guardant Health Recent Developments
  7. 6.2 Exact Sciences
  8. 6.2.1 Exact Sciences Company Information
  9. 6.2.2 Exact Sciences Business Overview
  10. 6.2.3 Exact Sciences NGS for Cancer Early Screening Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Exact Sciences NGS for Cancer Early Screening Product Portfolio
  12. 6.2.5 Exact Sciences Recent Developments
  13. 6.3 Freenome
  14. 6.3.1 Freenome Company Information
  15. 6.3.2 Freenome Business Overview
  16. 6.3.3 Freenome NGS for Cancer Early Screening Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Freenome NGS for Cancer Early Screening Product Portfolio
  18. 6.3.5 Freenome Recent Developments
  19. 6.4 Epiginomics AG
  20. 6.4.1 Epiginomics AG Company Information
  21. 6.4.2 Epiginomics AG Business Overview
  22. 6.4.3 Epiginomics AG NGS for Cancer Early Screening Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Epiginomics AG NGS for Cancer Early Screening Product Portfolio
  24. 6.4.5 Epiginomics AG Recent Developments
  25. 6.5 Bio-techne
  26. 6.5.1 Bio-techne Company Information
  27. 6.5.2 Bio-techne Business Overview
  28. 6.5.3 Bio-techne NGS for Cancer Early Screening Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Bio-techne NGS for Cancer Early Screening Product Portfolio
  30. 6.5.5 Bio-techne Recent Developments
  31. 6.6 ThriveEarlier Detection
  32. 6.6.1 ThriveEarlier Detection Company Information
  33. 6.6.2 ThriveEarlier Detection Business Overview
  34. 6.6.3 ThriveEarlier Detection NGS for Cancer Early Screening Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 ThriveEarlier Detection NGS for Cancer Early Screening Product Portfolio
  36. 6.6.5 ThriveEarlier Detection Recent Developments
  37. 6.7 GRAIL, Inc.
  38. 6.7.1 GRAIL, Inc. Company Information
  39. 6.7.2 GRAIL, Inc. Business Overview
  40. 6.7.3 GRAIL, Inc. NGS for Cancer Early Screening Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 GRAIL, Inc. NGS for Cancer Early Screening Product Portfolio
  42. 6.7.5 GRAIL, Inc. Recent Developments
  43. 6.8 CellMax life
  44. 6.8.1 CellMax life Company Information
  45. 6.8.2 CellMax life Business Overview
  46. 6.8.3 CellMax life NGS for Cancer Early Screening Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 CellMax life NGS for Cancer Early Screening Product Portfolio
  48. 6.8.5 CellMax life Recent Developments
  49. 6.9 Berry Genomics
  50. 6.9.1 Berry Genomics Company Information
  51. 6.9.2 Berry Genomics Business Overview
  52. 6.9.3 Berry Genomics NGS for Cancer Early Screening Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 Berry Genomics NGS for Cancer Early Screening Product Portfolio
  54. 6.9.5 Berry Genomics Recent Developments
  55. 6.10 Singlera Genomics
  56. 6.10.1 Singlera Genomics Company Information
  57. 6.10.2 Singlera Genomics Business Overview
  58. 6.10.3 Singlera Genomics NGS for Cancer Early Screening Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 Singlera Genomics NGS for Cancer Early Screening Product Portfolio
  60. 6.10.5 Singlera Genomics Recent Developments
  61. 6.11 Geneseeq
  62. 6.11.1 Geneseeq Company Information
  63. 6.11.2 Geneseeq Business Overview
  64. 6.11.3 Geneseeq NGS for Cancer Early Screening Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 Geneseeq NGS for Cancer Early Screening Product Portfolio
  66. 6.11.5 Geneseeq Recent Developments
  67. 6.12 BGI Genomics
  68. 6.12.1 BGI Genomics Company Information
  69. 6.12.2 BGI Genomics Business Overview
  70. 6.12.3 BGI Genomics NGS for Cancer Early Screening Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 BGI Genomics NGS for Cancer Early Screening Product Portfolio
  72. 6.12.5 BGI Genomics Recent Developments
  73. 6.13 Burning Rock Biotech Limited
  74. 6.13.1 Burning Rock Biotech Limited Company Information
  75. 6.13.2 Burning Rock Biotech Limited Business Overview
  76. 6.13.3 Burning Rock Biotech Limited NGS for Cancer Early Screening Revenue, Global Share and Gross Margin (2021-2026)
  77. 6.13.4 Burning Rock Biotech Limited NGS for Cancer Early Screening Product Portfolio
  78. 6.13.5 Burning Rock Biotech Limited Recent Developments
  79. 6.14 New Horizon Health Limited
  80. 6.14.1 New Horizon Health Limited Company Information
  81. 6.14.2 New Horizon Health Limited Business Overview
  82. 6.14.3 New Horizon Health Limited NGS for Cancer Early Screening Revenue, Global Share and Gross Margin (2021-2026)
  83. 6.14.4 New Horizon Health Limited NGS for Cancer Early Screening Product Portfolio
  84. 6.14.5 New Horizon Health Limited Recent Developments
  85. 6.15 Yeasen Bio
  86. 6.15.1 Yeasen Bio Company Information
  87. 6.15.2 Yeasen Bio Business Overview
  88. 6.15.3 Yeasen Bio NGS for Cancer Early Screening Revenue, Global Share and Gross Margin (2021-2026)
  89. 6.15.4 Yeasen Bio NGS for Cancer Early Screening Product Portfolio
  90. 6.15.5 Yeasen Bio Recent Developments
  91. 6.16 Hangzhou Aoru Biotech
  92. 6.16.1 Hangzhou Aoru Biotech Company Information
  93. 6.16.2 Hangzhou Aoru Biotech Business Overview
  94. 6.16.3 Hangzhou Aoru Biotech NGS for Cancer Early Screening Revenue, Global Share and Gross Margin (2021-2026)
  95. 6.16.4 Hangzhou Aoru Biotech NGS for Cancer Early Screening Product Portfolio
  96. 6.16.5 Hangzhou Aoru Biotech Recent Developments
  97. 6.17 Amoy Diagnostics Co., Ltd.
  98. 6.17.1 Amoy Diagnostics Co., Ltd. Company Information
  99. 6.17.2 Amoy Diagnostics Co., Ltd. Business Overview
  100. 6.17.3 Amoy Diagnostics Co., Ltd. NGS for Cancer Early Screening Revenue, Global Share and Gross Margin (2021-2026)
  101. 6.17.4 Amoy Diagnostics Co., Ltd. NGS for Cancer Early Screening Product Portfolio
  102. 6.17.5 Amoy Diagnostics Co., Ltd. Recent Developments
  103. 6.18 Genetron Health
  104. 6.18.1 Genetron Health Company Information
  105. 6.18.2 Genetron Health Business Overview
  106. 6.18.3 Genetron Health NGS for Cancer Early Screening Revenue, Global Share and Gross Margin (2021-2026)
  107. 6.18.4 Genetron Health NGS for Cancer Early Screening Product Portfolio
  108. 6.18.5 Genetron Health Recent Developments
  109. 6.19 AnchorDx
  110. 6.19.1 AnchorDx Company Information
  111. 6.19.2 AnchorDx Business Overview
  112. 6.19.3 AnchorDx NGS for Cancer Early Screening Revenue, Global Share and Gross Margin (2021-2026)
  113. 6.19.4 AnchorDx NGS for Cancer Early Screening Product Portfolio
  114. 6.19.5 AnchorDx Recent Developments
7 North America
  1. 7.1 North America NGS for Cancer Early Screening Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America NGS for Cancer Early Screening Market Size by Country (2021-2026)
  3. 7.3 North America NGS for Cancer Early Screening Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe NGS for Cancer Early Screening Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe NGS for Cancer Early Screening Market Size by Country (2021-2026)
  3. 8.3 Europe NGS for Cancer Early Screening Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific NGS for Cancer Early Screening Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific NGS for Cancer Early Screening Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific NGS for Cancer Early Screening Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America NGS for Cancer Early Screening Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America NGS for Cancer Early Screening Market Size by Country (2021-2026)
  3. 10.3 South America NGS for Cancer Early Screening Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa NGS for Cancer Early Screening Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa NGS for Cancer Early Screening Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa NGS for Cancer Early Screening Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst